Cargando…
Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma
BACKGROUND: With the feature of destructive and biliary malignancy, intrahepatic cholangiocarcinoma (ICC), presents unclear molecular mechanisms which contributes to typically poor prognosis for patients. Seizure-related 6 homolog-like 2 (SEZ6L2) is a gene that encodes for a seizure-associated prote...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798643/ https://www.ncbi.nlm.nih.gov/pubmed/35117286 http://dx.doi.org/10.21037/tcr-20-1527 |
_version_ | 1784641857960017920 |
---|---|
author | Wang, Ziming Lai, Jiaming Liang, Lijian Yin, Xiaoyu Wang, Qian Cheng, Quanyong Zheng, Chaoxu |
author_facet | Wang, Ziming Lai, Jiaming Liang, Lijian Yin, Xiaoyu Wang, Qian Cheng, Quanyong Zheng, Chaoxu |
author_sort | Wang, Ziming |
collection | PubMed |
description | BACKGROUND: With the feature of destructive and biliary malignancy, intrahepatic cholangiocarcinoma (ICC), presents unclear molecular mechanisms which contributes to typically poor prognosis for patients. Seizure-related 6 homolog-like 2 (SEZ6L2) is a gene that encodes for a seizure-associated protein localized on the cell surface. Thus far, the function of SEZ6L2 in ICC has not been reported. METHODS: We used data from The Cancer Genome Atlas and the Gene Expression Omnibus to analyze dynamics behind and levels of expression of SEZ6L2 in ICC. Then we used qRT-PCR and Immunohistochemical staining to detect levels of expression of SEZ6L2 and thereby determined the potential clinical significance of this protein in ICC. RESULTS: According to qRT-PCR and immunohistochemical analysis results, SEZ6L2 was overexpressed in ICC. Kaplan-Meier and Cox proportional hazard analyses indicated that patients afflicted by ICC with high levels of relative expression of SEZ6L2 have a poorer prognosis and that SEZ6L2 may be an independent prognostic factor which enables to the accurate prediction of overall survival (OS) and disease-free survivals’ (DFS) expected rates. Subcutaneous xenograft models used to explore the role of SEZ6L2 in tumor formation in vivo. The dynamics of the SEZ6L2 gene being promote angiogenesis in cholangiocarcinoma are related to increasing expressive growth factors which include EGF, VEGF, PDGF and the activation of the P38-MAPK pathway. CONCLUSIONS: Our findings suggest that SEZ6L2 can serve as an advanced biomarker that can be used to accurately predict a patient prognosis and be used as a target for ICC treatment. |
format | Online Article Text |
id | pubmed-8798643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-87986432022-02-02 Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma Wang, Ziming Lai, Jiaming Liang, Lijian Yin, Xiaoyu Wang, Qian Cheng, Quanyong Zheng, Chaoxu Transl Cancer Res Original Article BACKGROUND: With the feature of destructive and biliary malignancy, intrahepatic cholangiocarcinoma (ICC), presents unclear molecular mechanisms which contributes to typically poor prognosis for patients. Seizure-related 6 homolog-like 2 (SEZ6L2) is a gene that encodes for a seizure-associated protein localized on the cell surface. Thus far, the function of SEZ6L2 in ICC has not been reported. METHODS: We used data from The Cancer Genome Atlas and the Gene Expression Omnibus to analyze dynamics behind and levels of expression of SEZ6L2 in ICC. Then we used qRT-PCR and Immunohistochemical staining to detect levels of expression of SEZ6L2 and thereby determined the potential clinical significance of this protein in ICC. RESULTS: According to qRT-PCR and immunohistochemical analysis results, SEZ6L2 was overexpressed in ICC. Kaplan-Meier and Cox proportional hazard analyses indicated that patients afflicted by ICC with high levels of relative expression of SEZ6L2 have a poorer prognosis and that SEZ6L2 may be an independent prognostic factor which enables to the accurate prediction of overall survival (OS) and disease-free survivals’ (DFS) expected rates. Subcutaneous xenograft models used to explore the role of SEZ6L2 in tumor formation in vivo. The dynamics of the SEZ6L2 gene being promote angiogenesis in cholangiocarcinoma are related to increasing expressive growth factors which include EGF, VEGF, PDGF and the activation of the P38-MAPK pathway. CONCLUSIONS: Our findings suggest that SEZ6L2 can serve as an advanced biomarker that can be used to accurately predict a patient prognosis and be used as a target for ICC treatment. AME Publishing Company 2020-11 /pmc/articles/PMC8798643/ /pubmed/35117286 http://dx.doi.org/10.21037/tcr-20-1527 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Original Article Wang, Ziming Lai, Jiaming Liang, Lijian Yin, Xiaoyu Wang, Qian Cheng, Quanyong Zheng, Chaoxu Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma |
title | Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma |
title_full | Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma |
title_fullStr | Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma |
title_full_unstemmed | Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma |
title_short | Overexpression of SEZ6L2 predicts poor prognosis in patients with cholangiocarcinoma |
title_sort | overexpression of sez6l2 predicts poor prognosis in patients with cholangiocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798643/ https://www.ncbi.nlm.nih.gov/pubmed/35117286 http://dx.doi.org/10.21037/tcr-20-1527 |
work_keys_str_mv | AT wangziming overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma AT laijiaming overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma AT lianglijian overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma AT yinxiaoyu overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma AT wangqian overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma AT chengquanyong overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma AT zhengchaoxu overexpressionofsez6l2predictspoorprognosisinpatientswithcholangiocarcinoma |